We showed significant downregulation of RUNX1-RUNX1T1 expression following CRISPR editing in two of the patients (Fig. 5B) thus providing evidence that the CRISPR-Cas9-mediated method for fusion gene disruption is feasible also in patient-derived AML t(8;21) cancer cells. The gene discussed is RUNX1; the disease is acute myeloid leukemia.